Professor Roger Barker University positionProfessor DepartmentsDepartment of Clinical Neurosciences InstitutesCambridge Centre for Brain Repair Home pageResearch ThemesInterestsI work on: Clinical aspects of Parkinson's and Huntington's disease including the study of disease heterogeneity using cognitive testing, functional imaging and genetic biomarkers. Examining the value of different biomarkers to assess disease onset and progression. Evaluating and developing novel therapies for these conditions including cell transplants. Studying the effects of the neurodegenerative brain on intrinsic adult neurogenesis. Research Focus
EquipmentBehavioural analysis Cell culture Confocal microscopy Cross-sectional and cohort studies Fluorescence microscopy Immunohistochemistry Magnetic resonance imaging (MRI) Microscopy Neuropsychological testing Positron Emission Tomography (PET) Collaborators
Associated News Items
Key publicationsClelland CD, Choi M, Romberg C, Clemenson GD Jr, Fragniere A, Tyers P, Jessberger S, Saksida LM, Barker RA, Gage FH, Bussey TJ (2009), “A functional role for adult hippocampal neurogenesis in spatial pattern separation.” Science 325(5937):210-3 Details O'Keeffe GC, Tyers P, Aarsland D, Dalley JW, Barker RA, Caldwell MA (2009), “Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.” Proc Natl Acad Sci U S A 106(21):8754-9 Details Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ (2007), “Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.” Ann Neurol 62(2):145-53 Details Publications2014Ali FR, Cheng K, Kirwan P, Metcalfe S, Livesey FJ, Barker RA, Philpott A (2014), “The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro.” Development 141(11):2216-24 Details Barker RA (2014), “Editorial.” Neuropathol Appl Neurobiol 40(1):1-2 Barker RA, Mason SL (2014), “Neurodegenerative disease: Mapping the natural history of Huntington disease.” Nat Rev Neurol 10(1):12-3 Details Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA (2014), “Sleep and circadian rhythm regulation in early Parkinson disease.” JAMA Neurol 71(5):589-95 Details Buttery PC, Barker RA (2014), “Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?” J Comp Neurol 522(12):2802-16 Details Choi ML, Begeti F, Oh JH, Lee SY, O'Keeffe GC, Clelland CD, Tyers P, Cho ZH, Kim YB, Barker RA (2014), “Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.” Neurobiol Dis 66:19-27 Details Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper JN, Hauser RA, Mantovani D, Barker RA, Freeman TB (2014), “Mutant huntingtin is present in neuronal grafts in huntington disease patients.” Ann Neurol Details Collins LM, Lazic SE, Barker RA (2014), “A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease.” BMC Neurol 14:35 Details Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Tröster AI, Burn DJ, Litvan I, MDS Study Group on the Validation of PD-MCI Criteria (2014), “Parkinson's disease mild cognitive impairment: application and validation of the criteria.” J Parkinsons Dis 4(2):131-7 Details Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE (2014), “The spectrum of cognitive impairment in Lewy body diseases.” Mov Disord 29(5):608-21 Details Herva ME, Zibaee S, Fraser G, Barker RA, Goedert M, Spillantini MG (2014), “Anti-amyloid compounds inhibit ?-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA).” J Biol Chem 289(17):11897-905 Details Huefner A, Septiadi D, Wilts BD, Patel II, Kuan WL, Fragniere A, Barker RA, Mahajan S (2014), “Gold nanoparticles explore cells: Cellular uptake and their use as intracellular probes.” Methods 68(2):354-63 Details Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW (2014), “Targeting impulsivity in Parkinson's disease using atomoxetine.” Brain 137(Pt 7):1986-97 Details Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, Collerton D, Taylor JP, Burn DJ (2014), “Quality of Life and Mild Cognitive Impairment in Early Parkinson's Disease: Does Subtype Matter?” J Parkinsons Dis Details Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA, Researchers of the PREDICT-HD Huntington's Study Group (2014), “Tracking motor impairments in the progression of Huntington's disease.” Mov Disord 29(3):311-9 Details Moore SF, Barker RA (2014), “Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease.” Parkinsonism Relat Disord 20 Suppl 1:S104-7 Details Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA (2014), “Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.” Lancet Details Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, Nombela C, Winder-Rhodes S, Evans JR, Rowe JB, Mollenhauer B, Kruse N, Hudson G, Chinnery PF, O'Brien JT, Robbins TW, Wesnes K, Brooks DJ, Barker RA, Burn DJ, ICICLE-PD Study Group (2014), “Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study.” Neurology 82(4):308-16 Details Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB (2014), “Improving Response Inhibition in Parkinson's Disease with Atomoxetine.” Biol Psychiatry Details Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB (2014), “Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.” Brain 137(Pt 4):1145-55 Details 2013Ali F, Stott SR, Barker RA (2013), “Stem cells and the treatment of Parkinson's disease.” Exp Neurol Details Antoniades CA, Xu Z, Carpenter RH, Barker RA (2013), “The relationship between abnormalities of saccadic and manual response times in Parkinson's disease.” J Parkinsons Dis 3(4):557-63 Details Barker RA, Barrett J, Mason SL, Björklund A (2013), “Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease.” Lancet Neurol 12(1):84-91 Details Barker RA, de Beaufort I (2013), “Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain.” Prog Neurobiol 110:63-73 Details Barker RA, Filippi M, Strupp M (2013), “Journal of Neurology: ready for continued success.” J Neurol 260(1):1-2 Details Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB, NEST-UK collaboration (2013), “The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.” J Neurol Neurosurg Psychiatry 84(6):657-65 Details Barker RA, Stacy M, Brundin P (2013), “A new approach to disease-modifying drug trials in Parkinson's disease.” J Clin Invest 123(6):2364-5 Details Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA (2013), “The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease.” J Neurol 260(11):2777-85 Details Bonner-Jackson A, Long JD, Westervelt H, Tremont G, Aylward E, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2013), “Cognitive reserve and brain reserve in prodromal Huntington's Disease.” J Int Neuropsychol Soc 19(7):739-50 Details Breen DP, Evans JR, Farrell K, Brayne C, Barker RA (2013), “Determinants of delayed diagnosis in Parkinson's disease.” J Neurol 260(8):1978-81 Details Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA (2013), “Excessive daytime sleepiness and its risk factors in incident Parkinson's disease.” J Neurol Neurosurg Psychiatry 84(2):233-4 Details Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK (2013), “Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.” J Parkinsons Dis 3(3):231-9 Details Burn DJ, Barker RA (2013), “Mild cognitive impairment in Parkinson's disease: millstone or milestone?” Pract Neurol 13(2):68-9 Details Carri AD, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R, Spaiardi P, Talpo F, Toselli M, Martino G, Barker RA, Dunnett SB, Biella G, Cattaneo E (2013), “Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons.” Development 140(2):301-12 Details Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, Hauser RA, Barker RA, Cicchetti F (2013), “Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability.” Brain 136(Pt 2):433-43 Details Drouin-Ouellet J, Barker RA (2013), “The challenges of administering cell-based therapies to patients with Parkinson's disease.” Neuroreport 24(18):1000-4 Details Duncan GW, Khoo TK, Coleman SY, Brayne C, Yarnall AJ, O'Brien JT, Barker RA, Burn DJ (2013), “The incidence of Parkinson's disease in the North-East of England.” Age Ageing Details Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ (2013), “Health-related quality of life in early Parkinson's disease: The impact of nonmotor symptoms.” Mov Disord Details Ellul MA, Cross J, Barker RA (2013), “L-dopa responsive parkinsonism secondary to a subdural haematoma.” J Clin Neurosci 20(7):1022-4 Details Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, Groves M, Bijanki KR, Downing N, Williams JK, Long JD, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2013), “Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.” J Psychiatr Res 47(10):1423-31 Details Fallon SJ, Hampshire A, Williams-Gray CH, Barker RA, Owen AM (2013), “Putative cortical dopamine levels affect cortical recruitment during planning.” Neuropsychologia 51(11):2194-201 Details HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network (2013), “A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.” JAMA Neurol 70(1):25-33 Details Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ, REGISTRY investigators of the European Huntington's Disease Network (2013), “Suicidal ideation in a European Huntington's disease population.” J Affect Disord 151(1):248-58 Details Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, Morris HR, Williams-Gray CH, Barker RA, Singleton AB, Hardy J, Wood NE, Burn DJ, Chinnery PF (2013), “Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease.” Neurology 80(22):2042-8 Details Huefner A, Kuan WL, Barker RA, Mahajan S (2013), “Intracellular SERS nanoprobes for distinction of different neuronal cell types.” Nano Lett 13(6):2463-70 Details Kehagia AA, Barker RA, Robbins TW (2013), “Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.” Neurodegener Dis 11(2):79-92 Details Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, Burn DJ (2013), “The spectrum of nonmotor symptoms in early Parkinson disease.” Neurology 80(3):276-81 Details Larsen AT, Ohlsson AG, Polentarutti B, Barker RA, Phillips AR, Abu-Rmaileh R, Dickinson PA, Abrahamsson B, Ostergaard J, Müllertz A (2013), “Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation.” Eur J Pharm Sci 48(1-2):339-50 Details Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D, REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP (2013), “The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.” PLoS One 8(7):e68951 Details Nombela C, Rae CL, Grahn JA, Barker RA, Owen AM, Rowe JB (2013), “How often does music and rhythm improve patients' perception of motor symptoms in Parkinson's disease?” J Neurol 260(5):1404-5 Details Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB (2013), “The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders.” J Neurol Neurosurg Psychiatry 84(5):544-51 Details Stott SR, Barker RA (2013), “Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.” Eur J Neurosci Details Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR (2013), “The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study.” Eur J Neurol 20(9):1325-9 Details Weerasinghe AJ, Amin SA, Barker RA, Othman T, Romano AN, Parker Siburt CJ, Tisnado J, Lambert LA, Huxford T, Carrano CJ, Crumbliss AL (2013), “Borate as a synergistic anion for Marinobacter algicola ferric binding protein, FbpA: a role for boron in iron transport in marine life.” J Am Chem Soc 135(39):14504-7 Details Whitworth SR, Loftus AM, Skinner TC, Gasson N, Barker RA, Bucks RS, Thomas MG (2013), “Personality affects aspects of health-related quality of life in Parkinson's disease via psychological coping strategies.” J Parkinsons Dis 3(1):45-53 Details Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA (2013), “The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.” J Neurol Neurosurg Psychiatry 84(11):1258-64 Details Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, Duran R, Mencacci NE, Sawcer SJ, Barker RA (2013), “Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.” Brain 136(Pt 2):392-9 Details 2012Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, Long JD, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2012), “Striatal volume contributes to the prediction of onset of Huntington disease in incident cases.” Biol Psychiatry 71(9):822-8 Details Barker RA (2012), “New hands at the helm.” J Neurol 259(1):1-3 Details Barker RA (2012), “The future of stem cells in neurodegenerative disorders of the central nervous system.” CMAJ 184(6):631-2 Details Barker RA (2012), “Stem cells and neurodegenerative diseases: where is it all going?” Regen Med 7(6 Suppl):26-31 Details Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2012), “Development of the Huntington disease work function scale.” J Occup Environ Med 54(10):1300-8 Details Decressac M, Barker RA (2012), “Neuropeptide Y and its role in CNS disease and repair.” Exp Neurol 238(2):265-72 Details Drouin-Ouellet J, Barker RA (2012), “Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?” Stem Cells Int 2012:926147 Details Evans JR, Mason SL, Barker RA (2012), “Current status of clinical trials of neural transplantation in Parkinson's disease.” Prog Brain Res 200:169-98 Details Kehagia AA, Barker RA, Robbins TW (2012), “Revisiting the effects of Parkinson's disease and frontal lobe lesions on task switching: The role of rule reconfiguration.” J Neuropsychol Details Kuan WL, Poole E, Fletcher M, Karniely S, Tyers P, Wills M, Barker RA, Sinclair JH (2012), “A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.” J Exp Med 209(1):1-10 Details Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB, European Huntington’s Disease Network (2012), “Discrepancies in reporting the CAG repeat lengths for Huntington's disease.” Eur J Hum Genet 20(1):20-6 Details Winder-Rhodes SE, Garcia-Reitböck P, Ban M, Evans JR, Jacques TS, Kemppinen A, Foltynie T, Williams-Gray CH, Chinnery PF, Hudson G, Burn DJ, Allcock LM, Sawcer SJ, Barker RA, Spillantini MG (2012), “Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome.” Mov Disord 27(2):312-5 Details 2011Barker RA, Mason SL (2011), “Neurodegenerative disease: Tracking disease progress in Huntington disease.” Nat Rev Neurol 7(4):192-3 Details Breen DP, Michell AW, Barker RA (2011), “Parkinson's disease--the continuing search for biomarkers.” Clin Chem Lab Med 49(3):393-401 Details Breen DP, Rowe JB, Barker RA (2011), “Role of brain imaging in early parkinsonism.” BMJ 342:d638 Details Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, Tyers P, Barker RA, Kelly CM, Rosser AE, Stephens E, Chandran S, Caldwell MA (2011), “Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells.” Cell Death Differ 18(5):907-13 Details de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J, MermaiHD study investigators (2011), “Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.” Lancet Neurol 10(12):1049-57 Details Dyson SC, Barker RA (2011), “Cell-based therapies for Parkinson's disease.” Expert Rev Neurother 11(6):831-44 Details Evans JR, Barker RA (2011), “Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.” Expert Opin Pharmacother 12(8):1249-58 Details Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA (2011), “The natural history of treated Parkinson's disease in an incident, community based cohort.” J Neurol Neurosurg Psychiatry 82(10):1112-8 Details Goodman AO, Barker RA (2011), “Body composition in premanifest Huntington's disease reveals lower bone density compared to controls.” PLoS Curr 3:RRN1214 Details Goodman AO, Rogers L, Pilsworth S, McAllister CJ, Shneerson JM, Morton AJ, Barker RA (2011), “Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease.” Curr Neurol Neurosci Rep 11(2):211-7 Details Laguna Goya R, Busch R, Mathur R, Coles AJ, Barker RA (2011), “Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation.” Neurobiol Dis 41(2):407-14 Details McKenzie K, Barker RA, Scott DA, Strachan DA (2011), “Use of routine health data to complement monitoring of consumer product-related injuries.” Med J Aust 195(10):580-1 Details Nopoulos PC, Aylward EH, Ross CA, Mills JA, Langbehn DR, Johnson HJ, Magnotta VA, Pierson RK, Beglinger LJ, Nance MA, Barker RA, Paulsen JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2011), “Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment.” Brain 134(Pt 1):137-42 Details O'Keeffe GC, Barker RA (2011), “Dopamine stimulates epidermal growth factor release from adult neural precursor cells derived from the subventricular zone by a disintegrin and metalloprotease.” Neuroreport 22(18):956-8 Details Perneczky R, Ghosh BC, Hughes L, Carpenter RH, Barker RA, Rowe JB (2011), “Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity.” Neurobiol Dis 43(1):79-85 Details Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P (2011), “Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.” Hum Brain Mapp 32(2):258-70 Details UK Parkinson's Disease Consortium, Wellcome Trust Case Control Consortium 2, Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, Barker RA, Bellenguez C, Bhatia K, Blackburn H, Blackwell JM, Bramon E, Brown MA, Brown MA, Burn D, Casas JP, Chinnery PF, Clarke CE, Corvin A, Craddock N, Deloukas P, Edkins S, Evans J, Freeman C, Gray E, Hardy J, Hudson G, Hunt S, Jankowski J, Langford C, Lees AJ, Markus HS, Mathew CG, McCarthy MI, Morrison KE, Palmer CN, Pearson JP, Peltonen L, Pirinen M, Plomin R, Potter S, Rautanen A, Sawcer SJ, Su Z, Trembath RC, Viswanathan AC, Williams NW, Morris HR, Donnelly P, Wood NW (2011), “Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21.” Hum Mol Genet 20(2):345-53 Details Wijeyekoon R, Barker RA (2011), “The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review.” Front Integr Neurosci 5:78 Details 2010Breen DP, Barker RA (2010), “Parkinson's disease and 2009: recent advances.” J Neurol Details Decressac M, Wright B, David B, Tyers P, Jaber M, Barker RA, Gaillard A (2010), “Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis.” Hippocampus Details Goodman AO, Barker RA (2010), “How vital is sleep in Huntington's disease?” J Neurol Details Goodman AO, Morton AJ, Barker RA (2010), “Identifying sleep disturbances in Huntington's disease using a simple disease-focused questionnaire.” PLoS Curr 2:RRN1189 Details Hobbs NZ, Barnes J, Frost C, Henley SM, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ (2010), “Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study.” AJNR Am J Neuroradiol Details Hughes LE, Barker RA, Owen AM, Rowe JB (2010), “Parkinson's disease and healthy aging: Independent and interacting effects on action selection.” Hum Brain Mapp Details Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A, Dimebon in Subjects with Huntington Disease (DIMOND) Investigators of the Huntington Study Group (2010), “A randomized, placebo-controlled trial of latrepirdine in Huntington disease.” Arch Neurol 67(2):154-60 Details Laguna Goya R, Tyers P, Barker RA (2010), “Adult neurogenesis is unaffected by a functional knock-out of MHC class I in mice.” Neuroreport 21(5):349-53 Details Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2010), “CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.” Am J Med Genet B Neuropsychiatr Genet 153B(2):397-408 Details Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P (2010), “Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers.” Neurobiol Dis 37(2):356-61 Details Rowe JB, Hughes LE, Barker RA, Owen AM (2010), “Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment?” Neuroimage Details 2009Aziz NA, Jurgens CK, Landwehrmeyer GB, EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA (2009), “Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.” Neurology 73(16):1280-5 Details Barker RA (2009), “Parkinson's disease and growth factors - are they the answer?” Parkinsonism Relat Disord 15 Suppl 3:S181-4 Details Barker RA, Michell AW (2009), “"The eyes have it". Saccadometry and Parkinson's disease.” Exp Neurol Details Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group (2009), “Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.” Mov Disord 24(12):1763-72 Details Cools R, Rogers R, Barker RA, Robbins TW (2009), “Top-Down Attentional Control in Parkinson's Disease: Salient Considerations.” J Cogn Neurosci Details Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, Rothwell JC, Barker RA, Bhatia KP (2009), “BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.” J Neurol Neurosurg Psychiatry 80(2):141-4 Details Henley SM, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2009), “Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.” Mov Disord 24(6):932-6 Details Henley SM, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, Macmanus DG, Barker RA, Fox NC, Tabrizi SJ (2009), “Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.” J Neurol 256(2):203-12 Details Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA (2009), “Health-related quality of life in Huntington's disease: Which factors matter most?” Mov Disord 24(4):574-8 Details Hobbs NZ, Henley SM, Wild EJ, Leung KK, Frost C, Barker RA, Scahill RI, Barnes J, Tabrizi SJ, Fox NC (2009), “Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease.” Neuroimage 47(4):1659-65 Details Kehagia AA, Cools R, Barker RA, Robbins TW (2009), “Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease.” Neuropsychologia 47(4):1117-27 Details Lazic SE, Mason SL, Michell AW, Barker RA (2009), “Visualising disease progression on multiple variables with vector plots and path plots.” BMC Med Res Methodol 9:32 Details Lewis SJ, Barker RA (2009), “Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity.” J Clin Neurosci 16(5):620-5 Details Lewis SJ, Barker RA (2009), “A pathophysiological model of freezing of gait in Parkinson's disease.” Parkinsonism Relat Disord 15(5):333-8 Details Mason SL, Barker RA (2009), “Emerging drug therapies in Huntington's disease.” Expert Opin Emerg Drugs 14(2):273-97 Details O'Keeffe GC, Michell AW, Barker RA (2009), “Biomarkers in Huntington's and Parkinson's Disease.” Ann N Y Acad Sci 1180:97-110 Details O'Keeffe GI, Barker RA, Caldwell MA (2009), “Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain.” Cell Cycle 8(18) Details Phillips W, Michell A, Pruess H, Barker RA (2009), “Animal models of neurodegenerative diseases.” Methods Mol Biol 549:137-55 Details Thomas M, Tyers P, Lazic SE, Barker RA, Beazley L, Ziman M (2009), “Graft outcomes influenced by co-expression of Pax7 in graft and host tissue.” J Anat 214(3):396-405 Details Wijeyekoon R, Barker RA (2009), “Cell replacement therapy for Parkinson's disease.” Biochim Biophys Acta 1792(7):688-702 Details Williams-Gray C, Goris A, Foltynie T, Compston A, Sawcer S, Barker RA (2009), “No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson's disease.” J Neurol 256(1):132-3 Details Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009), “The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.” Brain 132(Pt 11):2958-69 Details Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA (2009), “Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.” J Neurol 256(3):493-8 Details 2008Antoniades CA, Barker RA (2008), “The search for biomarkers in Parkinson's disease: a critical review.” Expert Rev Neurother 8(12):1841-52 Details Blackwell AD, Paterson NS, Barker RA, Robbins TW, Sahakian BJ (2008), “The effects of modafinil on mood and cognition in Huntington's disease.” Psychopharmacology (Berl) Details Clelland CD, Barker RA, Watts C (2008), “Cell therapy in Huntington disease.” Neurosurg Focus 24(3-4):E9 Details Evans JR, Barker RA (2008), “Neurotrophic factors as a therapeutic target for Parkinson's disease.” Expert Opin Ther Targets 12(4):437-47 Details Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA (2008), “The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study.” Exp Neurol 210(2):691-8 Details Henley SM, Wild EJ, Hobbs NZ, Warren JD, Frost C, Scahill RI, Ridgway GR, MacManus DG, Barker RA, Fox NC, Tabrizi SJ (2008), “Defective emotion recognition in early HD is neuropsychologically and anatomically generic.” Neuropsychologia 46(8):2152-60 Details Kuan WL, Zhao JW, Barker RA (2008), “The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.” Psychopharmacology (Berl) 197(2):279-93 Details Laguna Goya R, Tyers P, Barker RA (2008), “The search for a curative cell therapy in Parkinson's disease.” J Neurol Sci 265(1-2):32-42 Details Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C (2008), “Incidence of early-onset dementias in Cambridgeshire, United Kingdom.” Neurology 71(19):1496-9 Details Michell AW, Goodman AO, Silva AH, Lazic SE, Morton AJ, Barker RA (2008), “Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease.” J Neurol 255(8):1145-52 Details Phillips W, Shannon KM, Barker RA (2008), “The current clinical management of Huntington's disease.” Mov Disord 23(11):1491-504 Details Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P (2008), “Hypothalamic involvement in Huntington's disease: an in vivo PET study.” Brain 131(Pt 11):2860-9 Details Quinn N, Barker RA, Wenning GK (2008), “Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?” Clin Pharmacol Ther 83(5):663-5 Details Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, Clough C, Brooks DJ, Barker RA, Piccini P (2008), “Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease.” J Neurol Neurosurg Psychiatry 79(8):948-51 Details Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM (2008), “Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.” Brain 131(Pt 8):2094-105 Details Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, Owen AM (2008), “The val(158)met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease.” Neurobiol Aging Details Thompson SA, Calvin J, Hogg S, Ferdinandusse S, Wanders RJ, Barker RA (2008), “Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency.” J Neurol Neurosurg Psychiatry 79(4):448-50 Details Wedderburn C, Wear H, Brown J, Mason SJ, Barker RA, Hodges J, Williams-Gray C (2008), “The utility of the Cambridge Behavioural Inventory in neurodegenerative disease.” J Neurol Neurosurg Psychiatry 79(5):500-3 Details Williams-Gray CH, Hampshire A, Barker RA, Owen AM (2008), “Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.” Brain 131(Pt 2):397-408 Details Wood NI, Goodman AO, van der Burg JM, Gazeau V, Brundin P, Björkqvist M, Petersén A, Tabrizi SJ, Barker RA, Jennifer Morton A (2008), “Increased thirst and drinking in Huntington's disease and the R6/2 mouse.” Brain Res Bull 76(1-2):70-9 Details 2007Antoniades CA, Altham PM, Mason SL, Barker RA, Carpenter R (2007), “Saccadometry: a new tool for evaluating presymptomatic Huntington patients.” Neuroreport 18(11):1133-6 Details Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007), “L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease.” Neuropsychopharmacology 32(1):180-9 Details Goris A, Williams-Gray CH, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Barker RA, Sawcer SJ (2007), “Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease.” J Neurol 254(7):846-8 Details Goya RL, Kuan WL, Barker RA (2007), “The future of cell therapies in the treatment of Parkinson's disease.” Expert Opin Biol Ther 7(10):1487-98 Details Kuan WL, Lin R, Tyers P, Barker RA (2007), “The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.” Neurobiol Dis 25(3):594-608 Details Lawrence AJ, Blackwell AD, Barker RA, Spagnolo F, Clark L, Aitken MR, Sahakian BJ (2007), “Predictors of punding in Parkinson's disease: results from a questionnaire survey.” Mov Disord 22(16):2339-45 Details Lazic SE, Goodman AO, Grote HE, Blakemore C, Morton AJ, Hannan AJ, van Dellen A, Barker RA (2007), “Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients.” Brain Res 1151:219-26 Details Michell AW, Tofaris GK, Gossage H, Tyers P, Spillantini MG, Barker RA (2007), “The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.” Cell Transplant 16(5):461-74 Details Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007), “Microglial activation in presymptomatic Huntington's disease gene carriers.” Brain 130(Pt 7):1759-66 Details Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P (2007), “Imaging microglial activation in Huntington's disease.” Brain Res Bull 72(2-3):148-51 Details Thomas MG, Barker RA, Beazley LD, Ziman MR (2007), “Pax7 expression in the adult rat superior colliculus following optic nerve injury.” Neuroreport 18(2):105-9 Details Williams-Gray CH, Barker RA (2007), “Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia.” Nat Clin Pract Neurol 3(5):250-1 Details Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007), “Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.” Brain 130(Pt 7):1787-98 Details Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA (2007), “Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease.” J Neurosci 27(18):4832-8 Details Wright BL, Barker RA (2007), “Established and emerging therapies for Huntington's disease.” Curr Mol Med 7(6):579-87 Details 2006Ali FR, Michell AW, Barker RA, Carpenter RH (2006), “The use of quantitative oculometry in the assessment of Huntington's disease.” Exp Brain Res 169(2):237-45 Details Barker RA (2006), “Continuing trials of GDNF in Parkinson's disease.” Lancet Neurol 5(4):285-6 Details Farrington M, Wreghitt TG, Lever AM, Dunnett SB, Rosser AE, Barker RA (2006), “Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature.” Cell Transplant 15(4):279-94 Details Goris A, Williams-Gray CH, Foltynie T, Compston DA, Barker RA, Sawcer SJ (2006), “No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening.” Am J Hum Genet 78(6):1088-90; author reply 1092-4 Details Harrower TP, Tyers P, Hooks Y, Barker RA (2006), “Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease.” Exp Neurol 197(1):56-69 Details Heath CA, Barker RA, Esmonde TF, Harvey P, Roberts R, Trend P, Head MW, Smith C, Bell JE, Ironside JW, Will RG, Knight RS (2006), “Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK.” J Neurol Neurosurg Psychiatry 77(7):880-2 Details Ho AK, Robbins AO, Barker RA (2006), “Huntington's disease patients have selective problems with insight.” Mov Disord 21(3):385-9 Details Jain M, Armstrong RJ, Elneil S, Barker RA (2006), “Transplanted human neural precursor cells migrate widely but show no lesion-specific tropism in the 6-hydroxydopamine rat model of Parkinson's disease.” Cell Transplant 15(7):579-93 Details Kuan WL, Hurelbrink CB, Barker RA (2006), “Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease.” Xenotransplantation 13(3):233-47 Details Lazic SE, Grote HE, Blakemore C, Hannan AJ, van Dellen A, Phillips W, Barker RA (2006), “Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment.” Eur J Neurosci 23(7):1829-38 Details Michell AW, Xu Z, Fritz D, Lewis SJ, Foltynie T, Williams-Gray CH, Robbins TW, Carpenter RH, Barker RA (2006), “Saccadic latency distributions in Parkinson's disease and the effects of L-dopa.” Exp Brain Res 174(1):7-18 Details Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006), “Microglial activation correlates with severity in Huntington disease: a clinical and PET study.” Neurology 66(11):1638-43 Details Phillips W, Jennifer Morton A, Barker RA (2006), “Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease.” Neuroreport 17(15):1623-7 Details Phillips W, Michell AW, Barker RA (2006), “Neurogenesis in diseases of the central nervous system.” Stem Cells Dev 15(3):359-79 Details Robbins AO, Ho AK, Barker RA (2006), “Weight changes in Huntington's disease.” Eur J Neurol 13(8):e7 Details Slabosz A, Lewis SJ, Smigasiewicz K, Szymura B, Barker RA, Owen AM (2006), “The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease.” Neuropsychology 20(5):578-88 Details Swainson R, SenGupta D, Shetty T, Watkins LH, Summers BA, Sahakian BJ, Polkey CE, Barker RA, Robbins TW (2006), “Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease.” Neuropsychologia 44(8):1290-304 Details Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC (2006), “Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles.” Brain 129(Pt 4):877-86 Details Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA (2006), “Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.” CNS Drugs 20(6):477-505 Details Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA (2006), “Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.” J Neurol Neurosurg Psychiatry 77(5):665-7 Details Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA (2006), “No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease.” Mov Disord 21(5):731-2 Details 2005Barker RA (2005), “The neurological assessment of patients in vegetative and minimally conscious states.” Neuropsychol Rehabil 15(3-4):214-23 Details Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ (2005), “Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease.” J Neurol Neurosurg Psychiatry 76(9):1204-10 Details Foltynie T, Hicks A, Sawcer S, Jonasdottir A, Setakis E, Maranian M, Yeo T, Lewis S, Brayne C, Stefansson K, Compston A, Gulcher J, Barker RA (2005), “A genome wide linkage disequilibrium screen in Parkinson's disease.” J Neurol 252(5):597-602 Details Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA (2005), “The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease.” J Neurol 252(7):833-8 Details Harrower T, Barker RA (2005), “Cell therapies for neurological disease--from bench to clinic to bench.” Expert Opin Biol Ther 5(3):289-91 Details Harrower TP, Michell AW, Barker RA (2005), “Lewy bodies in Parkinson's disease: protectors or perpetrators?” Exp Neurol 195(1):1-6 Details Hurelbrink CB, Barker RA (2005), “Migration of cells from primary transplants of allo- and xenografted foetal striatal tissue in the adult rat brain.” Eur J Neurosci 21(6):1503-10 Details Hurelbrink CB, Lewis SJ, Barker RA (2005), “The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease.” J Neurol 252(6):642-7 Details Kuan WL, Barker RA (2005), “New therapeutic approaches to Parkinson's disease including neural transplants.” Neurorehabil Neural Repair 19(3):155-81 Details Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA (2005), “Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.” J Neurol Neurosurg Psychiatry 76(3):343-8 Details Lewis SJ, Slabosz A, Robbins TW, Barker RA, Owen AM (2005), “Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.” Neuropsychologia 43(6):823-32 Details Longworth CE, Keenan SE, Barker RA, Marslen-Wilson WD, Tyler LK (2005), “The basal ganglia and rule-governed language use: evidence from vascular and degenerative conditions.” Brain 128(Pt 3):584-96 Details Michell AW, Barker RA, Raha SK, Raha-Chowdhury R (2005), “A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein.” J Neurol Neurosurg Psychiatry 76(4):596-7 Details Michell AW, Luheshi LM, Barker RA (2005), “Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease.” Neurosci Lett 381(3):294-8 Details Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES (2005), “Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.” J Neurosci 25(1):157-63 Details Phillips W, Morton AJ, Barker RA (2005), “Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment.” J Neurosci 25(50):11564-76 Details 2004Barker RA, Foltynie T (2004), “The future challenges in Parkinson's disease.” J Neurol 251(3):361-5 Details Barker RA, Widner H (2004), “Immune problems in central nervous system cell therapy.” NeuroRx 1(4):472-81 Details Foltynie T, Brayne CE, Robbins TW, Barker RA (2004), “The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.” Brain 127(Pt 3):550-60 Details Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR, Robbins TW, Barker RA (2004), “Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism.” Mov Disord 19(8):885-91 Details Foltynie T, Robbins YW, Brayne C, Barker RA (2004), “Cognitive impairments are common among a population cohort of newly diagnosed PD patients - the CamPaIGN study” Brain 127:550-60 Harrower TP, Barker RA (2004), “Is there a future for neural transplantation?” BioDrugs 18(3):141-53 Details Harrower TP, Barker RA (2004), “The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders.” Drugs Today (Barc) 40(2):171-89 Details Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA (2004), “Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue.” Xenotransplantation 11(1):60-71 Details Ho AK, Nestor PJ, Williams GB, Bradshaw JL, Sahakian BJ, Robbins TW, Barker RA (2004), “Pseudo-neglect in Huntington's disease correlates with decreased angular gyrus density.” Neuroreport 15(6):1061-4 Details Ho AK, Robbins AO, Walters SJ, Kaptoge S, Sahakian BJ, Barker RA (2004), “Health-related quality of life in Huntington's disease: a comparison of two generic instruments, SF-36 and SIP.” Mov Disord 19(11):1341-8 Details Ho AK, Sahakian BJ, Robbins TW, Barker RA (2004), “Random number generation in patients with symptomatic and presymptomatic Huntington's disease.” Cogn Behav Neurol 17(4):208-12 Details Hurelbrink CB, Barker RA (2004), “The potential of GDNF as a treatment for Parkinson's disease.” Exp Neurol 185(1):1-6 Details Lazic SE, Barker RA (2004), “Rapid decline in motor symptoms in HD neural transplant patients prior to surgery.” Brain Res Bull 63(1):83-4 Details Lazic SE, Grote H, Armstrong RJ, Blakemore C, Hannan AJ, van Dellen A, Barker RA (2004), “Decreased hippocampal cell proliferation in R6/1 Huntington's mice.” Neuroreport 15(5):811-3 Details Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM (2004), “Striatal contributions to working memory: a functional magnetic resonance imaging study in humans.” Eur J Neurosci 19(3):755-60 Details Michell AW, Lewis SJ, Foltynie T, Barker RA (2004), “Biomarkers and Parkinson's disease.” Brain 127(Pt 8):1693-705 Details Michell AW, Phillips W, Barker RA (2004), “Can endogenous stem cells be stimulated to repair the degenerating brain?” J Pharm Pharmacol 56(10):1201-10 Details Sayles M, Jain M, Barker RA (2004), “The cellular repair of the brain in Parkinson's disease--past, present and future.” Transpl Immunol 12(3-4):321-42 Details Wilkins A, Brown JM, Barker RA (2004), “SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: a case report.” Mov Disord 19(5):593-5 Details 2003Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, Barker RA (2003), “Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease.” Exp Brain Res 151(2):204-17 Details Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW (2003), “Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function.” J Cogn Neurosci 15(5):629-42 Details Barker RA, Foltynie T (2003), “How common is dementia with Lewy bodies?” J Neurol Neurosurg Psychiatry 74(6):697-8 Details Barker RA, Jain M, Armstrong RJ, Caldwell MA (2003), “Stem cells and neurological disease.” J Neurol Neurosurg Psychiatry 74(5):553-7 Details Browne GJ, Lam LT, Barker RA (2003), “The usefulness of a modified adult protocol for the clearance of paediatric cervical spine injury in the emergency department.” Emerg Med (Fremantle) 15(2):133-42 Details Cools R, Barker RA, Sahakian BJ, Robbins TW (2003), “L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease.” Neuropsychologia 41(11):1431-41 Details Ho AK, Manly T, Nestor PJ, Sahakian BJ, Bak TH, Robbins TW, Rosser AE, Barker RA (2003), “A case of unilateral neglect in Huntington's disease.” Neurocase 9(3):261-73 Details Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ané MN, Snowden J, Thompson J, Esmonde T, Gentry R, Moore JW, Bodner T, NEST-HD Consortium (2003), “Profile of cognitive progression in early Huntington's disease.” Neurology 61(12):1702-6 Details Hurelbrink CB, Tyers P, Armstrong RJ, Dunnett SB, Barker RA, Rosser AE (2003), “Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease.” Cell Transplant 12(7):687-95 Details Jain M, Armstrong RJ, Elneil S, Rosser AE, Barker RA (2003), “Migration and differentiation of transplanted human neural precursor cells.” Neuroreport 14(9):1257-62 Details Jain M, Armstrong RJ, Tyers P, Barker RA, Rosser AE (2003), “GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro.” Exp Neurol 182(1):113-23 Details Lazic SE, Barker RA (2003), “The future of cell-based transplantation therapies for neurodegenerative disorders.” J Hematother Stem Cell Res 12(6):635-42 Details Lewis SJ, Caldwell MA, Barker RA (2003), “Modern therapeutic approaches in Parkinson's disease.” Expert Rev Mol Med 5(10):1-20 Details Lewis SJ, Cools R, Robbins TW, Dove A, Barker RA, Owen AM (2003), “Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease.” Neuropsychologia 41(6):645-54 Details Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM (2003), “Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry.” J Neurosci 23(15):6351-6 Details Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P (2003), “Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.” Brain 126(Pt 5):1127-35 Details Rosser AE, Barker RA, Armstrong RJ, Elneil S, Jain M, Hurelbrink CB, Prentice A, Carne C, Thornton S, Hutchinson H, Dunnett SB (2003), “Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease.” Cell Transplant 12(7):679-86 Details 2002Armstrong RJ, Hurelbrink CB, Tyers P, Ratcliffe EL, Richards A, Dunnett SB, Rosser AE, Barker RA (2002), “The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease.” Exp Neurol 175(1):98-111 Details Barker RA (2002), “Repairing the brain in Parkinson's disease: where next?” Mov Disord 17(2):233-41 Details Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002), “Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.” Brain 125(Pt 3):584-94 Details Foltynie T, Brayne C, Barker RA (2002), “The heterogeneity of idiopathic Parkinson's disease.” J Neurol 249(2):138-45 Details Foltynie T, Sawcer S, Brayne C, Barker RA (2002), “The genetic basis of Parkinson's disease.” J Neurol Neurosurg Psychiatry 73(4):363-70 Details Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA (2002), “Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue.” Neuroreport 13(4):481-5 Details Ho AK, Sahakian BJ, Robbins TW, Barker RA, Rosser AE, Hodges JR (2002), “Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching.” Neuropsychologia 40(8):1277-84 Details Hurelbrink CB, Armstrong RJ, Dunnett SB, Rosser AE, Barker RA (2002), “Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS.” Eur J Neurosci 15(7):1255-66 Details Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB, NEST-UK (2002), “Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.” J Neurol Neurosurg Psychiatry 73(6):678-85 Details 2001Armstrong RJ, Barker RA (2001), “Neurodegeneration: a failure of neuroregeneration?” Lancet 358(9288):1174-6 Details Armstrong RJ, Harrower TP, Hurelbrink CB, McLaughin M, Ratcliffe EL, Tyers P, Richards A, Dunnett SB, Rosser AE, Barker RA (2001), “Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells.” Neuroscience 106(1):201-16 Details Barker RA (2001), “Getting to the heart of dementia.” J Neurol Neurosurg Psychiatry 71(5):574-5 Details Barker RA, Rosser AE (2001), “Neural transplantation therapies for Parkinson's and Huntington's diseases.” Drug Discov Today 6(11):575-582 Details Cools R, Barker RA, Sahakian BJ, Robbins TW (2001), “Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands.” Cereb Cortex 11(12):1136-43 Details Cools R, Barker RA, Sahakian BJ, Robbins TW (2001), “Mechanisms of cognitive set flexibility in Parkinson's disease.” Brain 124(Pt 12):2503-12 Details Hurelbrink CB, Armstrong RJ, Luheshi LM, Dunnett SB, Rosser AE, Barker RA (2001), “Death of dopaminergic neurons in vitro and in nigral grafts: reevaluating the role of caspase activation.” Exp Neurol 171(1):46-58 Details Hurelbrink CB, Barker RA (2001), “Prospects for the treatment of Parkinson's disease using neurotrophic factors.” Expert Opin Pharmacother 2(10):1531-43 Details Jain M, Armstrong RJ, Barker RA, Rosser AE (2001), “Cellular and molecular aspects of striatal development.” Brain Res Bull 55(4):533-40 Details 2000Barker RA (2000), “Prospects for the treatment of Parkinson's disease using neural grafts.” Expert Opin Pharmacother 1(5):889-902 Details Barker RA (2000), “Porcine neural xenografts: what are the issues?” Novartis Found Symp 231:184-96; discussion 196-201, 302-6 Details Barker RA, Kendall AL, Widner H (2000), “Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project.” Cell Transplant 9(2):235-46 Details Barker RA, Ratcliffe E, McLaughlin M, Richards A, Dunnett SB (2000), “A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease.” J Neurosci 20(9):3415-24 Details Hurelbrink CB, Armstrong RJ, Barker RA, Dunnett SB, Rosser AE (2000), “Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease.” Cell Transplant 9(6):743-9 Details 1999Barker RA, Anderson JR, Meyer P, Dick DJ, Scolding NJ (1999), “Microangiopathy of the brain and retina with hearing loss in a 50 year old woman: extending the spectrum of Susac's syndrome.” J Neurol Neurosurg Psychiatry 66(5):641-3 Details Barker RA, Dick DJ, Cochius JI (1999), “Delayed postanoxic encephalopathy and pseudodeficiency of arylsulphatase A.” J Neurol 246(11):1103-4 Details Barker RA, Dunnett SB (1999), “Functional integration of neural grafts in Parkinson's disease.” Nat Neurosci 2(12):1047-8 Details Barker RA, Dunnett SB, Richards A (1999), “The rejection of neural xenotransplants: a role for antibodies.” Transplantation 68(8):1091-2 Details Barker RA, Ratcliffe E, Richards A, Dunnett SB (1999), “Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age.” Cell Transplant 8(6):593-9 Details 1998Barker RA, Revesz T, Thom M, Marsden CD, Brown P (1998), “Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity.” J Neurol Neurosurg Psychiatry 65(5):633-40 Details Dunnett SB, Torres EM, Richards H, Barker RA (1998), “Effects of surgical anaesthesia on the viability of nigral grafts in the rat striatum.” Cell Transplant 7(6):567-72 Details Molyneux PD, Barker RA, Thom M, van Paesschen W, Harkness WF, Duncan JS (1998), “Successful treatment of intractable epilepsia partialis continua with multiple subpial transections.” J Neurol Neurosurg Psychiatry 65(1):137-8 Details 1997Annett LE, Torres EM, Clarke DJ, Ishida Y, Barker RA, Ridley RM, Baker HF, Dunnett SB (1997), “Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age.” Cell Transplant 6(6):557-69 Details 1996Barker RA, Dunnett SB, Faissner A, Fawcett JW (1996), “The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum.” Exp Neurol 141(1):79-93 Details Fricker RA, Barker RA, Fawcett JW, Dunnett SB (1996), “A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures, and in vivo grafts.” Cell Transplant 5(6):599-611 Details 1995Barker RA, Fricker RA, Abrous DN, Fawcett J, Dunnett SB (1995), “A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts.” Cell Transplant 4(2):173-200 Details Fawcett JW, Barker RA, Dunnett SB (1995), “Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon.” Exp Brain Res 106(2):275-82 Details |